Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Anti-CD38 mAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD38, His Tag (Cat. No. CD8-H5224) with an affinity constant of 4.98 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Daratumumab/Hyaluronidase-fihj | Approved | Janssen Global Services Llc | Darzalex Faspro, Darzquro | Japan | Amyloidosis | Janssen Pharmaceutical Kk | 2020-05-01 | Multiple Myeloma; Rejection of organ transplantation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Amyloidosis; Rejection in heart transplantation | Details | |
Isatuximab | SAR-650984 | Approved | Immunogen Inc | Sarclisa | Japan | Multiple Myeloma | Sanofi | 2020-03-02 | Gastrointestinal Hemorrhage; Leukemia, Myeloid, Acute; Macroglossia; Lymphoma; Nausea; Hepatomegaly; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Satiety Response; Diarrhea; Hematologic Neoplasms; Multiple Myeloma; Neoplasms; Purpura; Immunoglobulin Light-chain Amyloidosis; Smoldering Multiple Myeloma; Lymphadenopathy; Paraproteinemias; Constipation; Goiter, Nodular | Details |
Daratumumab | JNJ-54767414 | Approved | Janssen Global Services Llc | Darzalex, 兆珂, 兆珂速 | Mainland China | Multiple Myeloma | Janssen-Cilag International Nv | 2015-11-16 | Urinary Bladder Neoplasms; Hypersensitivity; POEMS Syndrome; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Urologic Neoplasms; Alzheimer Disease; Amyloidosis; Lymphoma, Extranodal NK-T-Cell; Prostatic Neoplasms; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Rejection of renal transplantation; Rejection of organ transplantation; Multiple Myeloma; Glioblastoma; Immunoglobulin Light-chain Amyloidosis; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Hodgkin Disease; Smoldering Multiple Myeloma; Carcinoma, Renal Cell; Genital Neoplasms, Male; Paraproteinemias; Kidney Neoplasms; Purpura, Thrombocytopenic, Idiopathic | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
XmAb-968 | XmAb968 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Leukemia, Promyelocytic, Acute | Details |
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Wuhan Union Hospital, Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
GBR-1342 | GBR-1342; ISB-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | Multiple Myeloma | Details |
64Cu-DOTA-daratumumab | Phase 1 Clinical | City Of Hope National Medical Center | Multiple Myeloma | Details | |
CART-38 | CART-38 | The First Affiliated Hospital Of Soochow University | Details | ||
Recombinant human anti-CD38 momoclonal antibody(Sumgen) | SG-301; SG301 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms | Details |
Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | Y-150; Y150 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd | Multiple Myeloma | Details |
CID-103 | CID-103; TSK011010 | Phase 1 Clinical | Tusk Therapeutics Ltd | Multiple Myeloma | Details |
SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
SG-2501 | SG-2501 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Lymphoma | Details |
TNB-738 | TNB-738 | Phase 1 Clinical | Details | ||
Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) | Phase 1 Clinical | Celularity Inc, Sorrento Therapeutics Inc | Multiple Myeloma | Details | |
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
89Zr-DFO-daratumumab | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details | |
Anti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology) | CAR-T CD-38 | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
CART-38(University of Pennsylvania) | CART-38 | Phase 1 Clinical | University Of Pennsylvania | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
ISB-1442 | ISB 1442; ISB-1442 | Phase 2 Clinical | Ichnos Sciences Sa | Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
XmAb-18968 | XmAb-18968 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Leukemia, Myeloid, Acute | Details |
CM-313(Connaught Biomedical Technology) | CM-313 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma | Details |
Modakafusp alfa | TEV-48573; TAK-573 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Neoplasms; Multiple Myeloma; Melanoma | Details |
KP-1237 | Phase 2 Clinical | Biohaven Pharmaceuticals Inc | Multiple Myeloma | Details | |
Mezagitamab | TAK-079 | Phase 2 Clinical | Takeda | Hematologic Neoplasms; Myasthenia Gravis; Purpura, Thrombocytopenic, Idiopathic; Glomerulonephritis, IGA; Nephrosis; Kidney Diseases; Autoimmune Diseases; Multiple Myeloma; Lupus Erythematosus, Systemic | Details |
211At-OKT10-B10 | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Multiple Myeloma | Details | |
STI-6129 | STI-6129; LNDS-1001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Solid tumours; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
TAK-169 | TAK-169 | Phase 1 Clinical | Molecular Templates Inc | Multiple Myeloma; Lymphoma, Non-Hodgkin | Details |
GEN-3014 | GEN-3014 | Phase 2 Clinical | Genmab A/S | Multiple Myeloma | Details |
Felzartamab | TJ-202; MOR-202; MOR-03087 | Phase 3 Clinical | Morphosys Ag | Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Multiple Myeloma; Rejection of organ transplantation; Lupus Erythematosus, Systemic; Glomerulonephritis | Details |
This web search service is supported by Google Inc.